Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myeloma
IntroductionEvaluating predictive biomarkers early in treatment, clinicians can anticipate Q7 77 78 survival outcomes. Ferritin has emerged as a promising predictor of clinical 79 outcomes in multiple myeloma (MM) patients undergoing chimeric antigen patient responses and tailor therapeutic strategi...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Hematology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frhem.2025.1618331/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849404689580294144 |
|---|---|
| author | Eider F. Moreno-Cortes Eider F. Moreno-Cortes Mariano Arribas David A. Martinez-Gamboa David A. Martinez-Gamboa Juana Figueroa-Aguirre Juana Figueroa-Aguirre Rohan Patel Daniel Bihnam Udit Yadav J. Erin Wiedmeier-Nutor Leif Bergsagel Saurabh Chhabra Rafael Fonseca Januario E. Castro Januario E. Castro |
| author_facet | Eider F. Moreno-Cortes Eider F. Moreno-Cortes Mariano Arribas David A. Martinez-Gamboa David A. Martinez-Gamboa Juana Figueroa-Aguirre Juana Figueroa-Aguirre Rohan Patel Daniel Bihnam Udit Yadav J. Erin Wiedmeier-Nutor Leif Bergsagel Saurabh Chhabra Rafael Fonseca Januario E. Castro Januario E. Castro |
| author_sort | Eider F. Moreno-Cortes |
| collection | DOAJ |
| description | IntroductionEvaluating predictive biomarkers early in treatment, clinicians can anticipate Q7 77 78 survival outcomes. Ferritin has emerged as a promising predictor of clinical 79 outcomes in multiple myeloma (MM) patients undergoing chimeric antigen patient responses and tailor therapeutic strategies to enhance efficacy and 80 receptor (CAR) T-cell therapy.MethodsIn this study, we investigated the prognostic 81 value of ferritin and C-reactive protein (CRP) as biomarkers in CAR T-cell 82 83 ferritin and CRP levels at two time points pre-infusion (Day-0) and pre- 84 lymphodepleting chemotherapy (LDC) and their association with clinical therapy for MM. This study’s objective was to evaluate the correlation between 85 response outcomes. We retrospectively analyzed outcomes from 52 relapsed/ 86 refractory MM (RRMM) patients who received either idecabtagene vicleucel or 87 ciltacabtagene autoleucel CAR T-cell therapies.ResultsLow ferritin levels at Day-0 and 88 pre-LDC were able to predict better responses regardless of the CAR T cell 89 product (hazard ratio [HR] 0.01 (95% CI 0.05–0.5); p=0.001, (HR 0.05 95% CI 90 0.01-0.2, p=<0.0069), respectively. Low ferritin + low CRP were able to predict responses at Day-0 and pre-LDC HR 0.3 (95% CI 0.07-1.3); p=0.04, HR 0.26 (95% CI 0.03-2.1), p=0.04, respectively.DiscussionOur results indicate that ferritin and CRP 93 levels represent promising predictive biomarkers that may refine CAR T-cell 94 therapy response by enabling better patient stratification and personalized 95 treatment approaches. Our study underscores the need for their integration 96 into routine clinical practice for MM management.ConclusionsFuture prospective studies are 97 warranted to validate these findings and explore the mechanistic link between 98 99 100 101 102 elevated ferritin levels, immune activation states, and CAR T-cell efficacy. |
| format | Article |
| id | doaj-art-51a6c2b5507841d9af3c8ffe391b64d1 |
| institution | Kabale University |
| issn | 2813-3935 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Hematology |
| spelling | doaj-art-51a6c2b5507841d9af3c8ffe391b64d12025-08-20T03:36:54ZengFrontiers Media S.A.Frontiers in Hematology2813-39352025-08-01410.3389/frhem.2025.16183311618331Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myelomaEider F. Moreno-Cortes0Eider F. Moreno-Cortes1Mariano Arribas2David A. Martinez-Gamboa3David A. Martinez-Gamboa4Juana Figueroa-Aguirre5Juana Figueroa-Aguirre6Rohan Patel7Daniel Bihnam8Udit Yadav9J. Erin Wiedmeier-Nutor10Leif Bergsagel11Saurabh Chhabra12Rafael Fonseca13Januario E. Castro14Januario E. Castro15Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesCancer Research and Cellular Therapy Laboratory, Mayo Clinic, Arizona, Phoenix, AZ, United StatesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesCancer Research and Cellular Therapy Laboratory, Mayo Clinic, Arizona, Phoenix, AZ, United StatesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesCancer Research and Cellular Therapy Laboratory, Mayo Clinic, Arizona, Phoenix, AZ, United StatesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesDivision of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, United StatesCancer Research and Cellular Therapy Laboratory, Mayo Clinic, Arizona, Phoenix, AZ, United StatesIntroductionEvaluating predictive biomarkers early in treatment, clinicians can anticipate Q7 77 78 survival outcomes. Ferritin has emerged as a promising predictor of clinical 79 outcomes in multiple myeloma (MM) patients undergoing chimeric antigen patient responses and tailor therapeutic strategies to enhance efficacy and 80 receptor (CAR) T-cell therapy.MethodsIn this study, we investigated the prognostic 81 value of ferritin and C-reactive protein (CRP) as biomarkers in CAR T-cell 82 83 ferritin and CRP levels at two time points pre-infusion (Day-0) and pre- 84 lymphodepleting chemotherapy (LDC) and their association with clinical therapy for MM. This study’s objective was to evaluate the correlation between 85 response outcomes. We retrospectively analyzed outcomes from 52 relapsed/ 86 refractory MM (RRMM) patients who received either idecabtagene vicleucel or 87 ciltacabtagene autoleucel CAR T-cell therapies.ResultsLow ferritin levels at Day-0 and 88 pre-LDC were able to predict better responses regardless of the CAR T cell 89 product (hazard ratio [HR] 0.01 (95% CI 0.05–0.5); p=0.001, (HR 0.05 95% CI 90 0.01-0.2, p=<0.0069), respectively. Low ferritin + low CRP were able to predict responses at Day-0 and pre-LDC HR 0.3 (95% CI 0.07-1.3); p=0.04, HR 0.26 (95% CI 0.03-2.1), p=0.04, respectively.DiscussionOur results indicate that ferritin and CRP 93 levels represent promising predictive biomarkers that may refine CAR T-cell 94 therapy response by enabling better patient stratification and personalized 95 treatment approaches. Our study underscores the need for their integration 96 into routine clinical practice for MM management.ConclusionsFuture prospective studies are 97 warranted to validate these findings and explore the mechanistic link between 98 99 100 101 102 elevated ferritin levels, immune activation states, and CAR T-cell efficacy.https://www.frontiersin.org/articles/10.3389/frhem.2025.1618331/fullCAR T cellmultiple myelomaferritinC reactive protein (CRP)ciltacabtagene autoleucelidecabtagene vicleucel |
| spellingShingle | Eider F. Moreno-Cortes Eider F. Moreno-Cortes Mariano Arribas David A. Martinez-Gamboa David A. Martinez-Gamboa Juana Figueroa-Aguirre Juana Figueroa-Aguirre Rohan Patel Daniel Bihnam Udit Yadav J. Erin Wiedmeier-Nutor Leif Bergsagel Saurabh Chhabra Rafael Fonseca Januario E. Castro Januario E. Castro Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myeloma Frontiers in Hematology CAR T cell multiple myeloma ferritin C reactive protein (CRP) ciltacabtagene autoleucel idecabtagene vicleucel |
| title | Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myeloma |
| title_full | Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myeloma |
| title_fullStr | Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myeloma |
| title_full_unstemmed | Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myeloma |
| title_short | Pre-infusion ferritin a predictive biomarker for CAR T-cell therapy in R/R multiple myeloma |
| title_sort | pre infusion ferritin a predictive biomarker for car t cell therapy in r r multiple myeloma |
| topic | CAR T cell multiple myeloma ferritin C reactive protein (CRP) ciltacabtagene autoleucel idecabtagene vicleucel |
| url | https://www.frontiersin.org/articles/10.3389/frhem.2025.1618331/full |
| work_keys_str_mv | AT eiderfmorenocortes preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT eiderfmorenocortes preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT marianoarribas preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT davidamartinezgamboa preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT davidamartinezgamboa preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT juanafigueroaaguirre preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT juanafigueroaaguirre preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT rohanpatel preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT danielbihnam preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT udityadav preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT jerinwiedmeiernutor preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT leifbergsagel preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT saurabhchhabra preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT rafaelfonseca preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT januarioecastro preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma AT januarioecastro preinfusionferritinapredictivebiomarkerforcartcelltherapyinrrmultiplemyeloma |